Findings

What do systematic reviews say?

4,919 questions · 13,869 findings · 2,177 reviews · Headline outcomes only

Sort:Best matchNewestHighest certainty Download CSV

No studies found 13,869 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy vs placebo

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Xpert Ultra result

The review found no eligible studies for this question.

1 finding from 1 review

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Xpert MTB/RIF result

The review found no eligible studies for this question.

1 finding from 1 review

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Xpert Ultra result

The review found no eligible studies for this question.

1 finding from 1 review

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Xpert MTB/RIF result

The review found no eligible studies for this question.

1 finding from 1 review

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Xpert Ultra result

The review found no eligible studies for this question.

1 finding from 1 review

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Xpert MTB/RIF result

The review found no eligible studies for this question.

1 finding from 1 review

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Xpert MTB/RIF result

The review found no eligible studies for this question.

1 finding from 1 review

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Xpert Ultra result

The review found no eligible studies for this question.

1 finding from 1 review

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: serious adverse events (MEC) when vs treatment with granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of Findings Table ‐ Low vs moderate‐high nasal continuous positive airway pressure levels

BPD at 28 days · health problem or population

The review found no eligible studies for this question.

1 finding from 1 review

Nasal continuous positive airway pressure levels for the prevention of morbidity and mortality in preterm infants 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of Findings Table ‐ Low vs moderate‐high nasal continuous positive airway pressure levels

Moderate‐severe neurodevelopmental impairment at 18 to 26 months ‐ not measured · health problem or population

The review found no eligible studies for this question.

2 findings from 1 review

Nasal continuous positive airway pressure levels for the prevention of morbidity and mortality in preterm infants 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Nasal continuous positive airway pressure levels for the prevention of morbidity and mortality in preterm infants 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Primary outcomes · Older adults living independently in the community

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing sedentary behaviour in community‐dwelling older adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Secondary outcomes · Older adults living independently in the community

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing sedentary behaviour in community‐dwelling older adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse effects · Older adults living independently in the community

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing sedentary behaviour in community‐dwelling older adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Enteral zinc supplementation vs no zinc supplementation

Growth · preterm infants

The review found no eligible studies for this question.

1 finding from 1 review

Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found